401 related articles for article (PubMed ID: 3104273)
1. Combined imipenem/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis.
Pedersen SS; Pressler T; Jensen T; Rosdahl VT; Bentzon MW; Høiby N; Koch C
J Antimicrob Chemother; 1987 Jan; 19(1):101-7. PubMed ID: 3104273
[TBL] [Abstract][Full Text] [Related]
2. Imipenem/cilastatin treatment of multiresistant Pseudomonas aeruginosa lung infection in cystic fibrosis.
Pedersen SS; Pressler T; Høiby N; Bentzon MW; Koch C
J Antimicrob Chemother; 1985 Nov; 16(5):629-35. PubMed ID: 3935639
[TBL] [Abstract][Full Text] [Related]
3. Imipenem/cilastatin, an alternative treatment of pseudomonas infection in cystic fibrosis.
Strandvik B; Malmborg AS; Bergan T; Michalsen H; Storrøsten OT; Wretlind B
J Antimicrob Chemother; 1988 Apr; 21(4):471-80. PubMed ID: 3132441
[TBL] [Abstract][Full Text] [Related]
4. Imipenem-cilastatin sodium, a broad-spectrum carbapenem antibiotic combination.
Pastel DA
Clin Pharm; 1986 Sep; 5(9):719-36. PubMed ID: 3530614
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Balke B; Hogardt M; Schmoldt S; Hoy L; Weissbrodt H; Häussler S
Eur J Clin Microbiol Infect Dis; 2006 Jan; 25(1):25-30. PubMed ID: 16402226
[TBL] [Abstract][Full Text] [Related]
6. Treatment of endocarditis due to Pseudomonas aeruginosa with imipenem.
Fichtenbaum CJ; Smith MJ
Clin Infect Dis; 1992 Jan; 14(1):353-4. PubMed ID: 1571451
[TBL] [Abstract][Full Text] [Related]
7. Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa.
Weiss K; Lapointe JR
Antimicrob Agents Chemother; 1995 Nov; 39(11):2411-4. PubMed ID: 8585718
[TBL] [Abstract][Full Text] [Related]
8. [Imipenem/cilastatin: in vitro activity, concentrations in plasma and prostatic adenoma and therapeutic results in patients with complicated urinary tract infections].
Naber KG; Adam D; Bauernfeind A; Hönig E
Infection; 1986; 14 Suppl 2():S122-9. PubMed ID: 2428754
[TBL] [Abstract][Full Text] [Related]
9. Imipenem/cilastatin in acute pulmonary exacerbations of cystic fibrosis.
Krilov LR; Blumer JL; Stern RC; Hartstein AI; Iglewski BN; Goldmann DA
Rev Infect Dis; 1985; 7 Suppl 3():S482-9. PubMed ID: 3901211
[TBL] [Abstract][Full Text] [Related]
10. Antibiotic treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients.
Møller NE; Høiby N
Scand J Infect Dis Suppl; 1981; 29():87-91. PubMed ID: 6458884
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis.
Blumer JL; Saiman L; Konstan MW; Melnick D
Chest; 2005 Oct; 128(4):2336-46. PubMed ID: 16236892
[TBL] [Abstract][Full Text] [Related]
12. [Development of resistance in imipenem therapy in Pseudomonas aeruginosa].
Krech T; Naumann P
Immun Infekt; 1986 Nov; 14(6):224-6. PubMed ID: 3100426
[TBL] [Abstract][Full Text] [Related]
13. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of bronchopulmonary infections in patients during artificial respiration with imipenem/cilastatin].
Unertl K; Lenhart FP; Ruckdeschel G
Immun Infekt; 1986 Nov; 14(6):229-31. PubMed ID: 3100428
[TBL] [Abstract][Full Text] [Related]
15. Imipenem-cilastatin: the first thienamycin antibiotic.
Jacobs RF
Pediatr Infect Dis; 1986; 5(4):444-8. PubMed ID: 3523460
[No Abstract] [Full Text] [Related]
16. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
Cheer SM; Waugh J; Noble S
Drugs; 2003; 63(22):2501-20. PubMed ID: 14609360
[TBL] [Abstract][Full Text] [Related]
17. Determination of synergy by two methods with eight antimicrobial combinations against tobramycin-susceptible and tobramycin-resistant strains of Pseudomonas.
Chan EL; Zabransky RJ
Diagn Microbiol Infect Dis; 1987 Feb; 6(2):157-64. PubMed ID: 3102156
[TBL] [Abstract][Full Text] [Related]
18. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multi-clinic study.
Norrby SR; Vandercam B; Louie T; Runde V; Norberg B; Anniko M; Andrien F; Baudrihaye M; Bow E; Burman LA
Scand J Infect Dis Suppl; 1987; 52():65-78. PubMed ID: 3331044
[TBL] [Abstract][Full Text] [Related]
19. Imipenem/cilastatin: the first carbapenem antibiotic.
Lyon JA
Drug Intell Clin Pharm; 1985 Dec; 19(12):895-9. PubMed ID: 3910385
[TBL] [Abstract][Full Text] [Related]
20. [In vitro interaction of piperacillin and imipenem/cilastatin combined with aminoglycosides against Pseudomonas aeruginosa].
Yamashiro Y; Ogake N; Takahata M; Minami S
Jpn J Antibiot; 2000 Apr; 53(4):194-200. PubMed ID: 10868299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
